Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics
Summary
Insilico Medicine announced first-in-human dosing for its AI-designed NLRP3 inhibitor ISM8969 in a Phase I study. The trial will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy and obese adult participants in Australia. Insilico is running the study with Hygtia Therapeutics under a global co-development agreement and may receive up to $66 million in milestone payments. The company also highlighted its AI and automation platform, including MMAI Gym, as part of its broader drug discovery strategy.
Classifications
industries
No industries detected
applications
Data Management
AskAI Classifications
Labels
SaaS
AI/ML Platforms
Bioinformatics Software
Linked Companies
Insilico Medicine
$25M to $50M